0000950170-24-082485.txt : 20240709
0000950170-24-082485.hdr.sgml : 20240709
20240709173003
ACCESSION NUMBER: 0000950170-24-082485
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240705
FILED AS OF DATE: 20240709
DATE AS OF CHANGE: 20240709
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Michaelson Jennifer
CENTRAL INDEX KEY: 0001838061
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39856
FILM NUMBER: 241108199
MAIL ADDRESS:
STREET 1: C/O CULLINAN MANAGEMENT, INC.
STREET 2: ONE MAIN STREET SUITE 520
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Cullinan Therapeutics, Inc.
CENTRAL INDEX KEY: 0001789972
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 813867811
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: ONE MAIN STREET
STREET 2: SUITE 1350
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 617-410-4650
MAIL ADDRESS:
STREET 1: ONE MAIN STREET
STREET 2: SUITE 1350
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
FORMER COMPANY:
FORMER CONFORMED NAME: Cullinan Oncology, Inc.
DATE OF NAME CHANGE: 20210225
FORMER COMPANY:
FORMER CONFORMED NAME: Cullinan Management, Inc.
DATE OF NAME CHANGE: 20210107
FORMER COMPANY:
FORMER CONFORMED NAME: Cullinan Oncology, LLC
DATE OF NAME CHANGE: 20191001
4
1
ownership.xml
4
X0508
4
2024-07-05
0001789972
Cullinan Therapeutics, Inc.
CGEM
0001838061
Michaelson Jennifer
C/O CULLINAN THERAPEUTICS, INC.
ONE MAIN STREET, SUITE 1350
CAMBRIDGE
MA
02142
false
true
false
false
Chief Scientific Officer
true
Common Stock
2024-07-05
4
S
false
8000
16.33
D
123942
D
Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on January 5, 2024.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $15.97 to $16.77. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
/s/ Jacquelyn Sumer, Attorney-in-Fact
2024-07-09